SCHEMBL17479215

SCHEMBL17479215

O=C(O)c1cccc(S(=O)(=O)NC2CCCCCC2)c1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.78
LMNA P02545 5/20 0.78
KMT2A Q03164 3/20 0.78
EPHX2 P34913 1/20 0.57
MEN1 O00255 2/20 0.56
KDM4E B2RXH2 3/20 0.55
HTT P42858 3/20 0.55
HPGD P15428 2/20 0.55
NPSR1 Q6W5P4 2/20 0.55
TSHR P16473 1/20 0.55
MAPK1 P28482 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
RECQL P46063 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
CYP2C19 P33261 1/20 0.52
POLB P06746 1/20 0.52
GFER P55789 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL925723 1.00 ALDH1A1 (0.78) ALDH1A1LMNAKMT2AEPHX2MEN1
SCHEMBL15575103 0.99 ALDH1A1 (0.75) ALDH1A1LMNAKMT2AEPHX2MEN1
SCHEMBL26144898 0.96 LMNA (0.71) ALDH1A1LMNAKMT2AEPHX2MEN1
SCHEMBL3940478 0.93 LMNA (0.76) ALDH1A1LMNAKMT2AKDM4ETSHR
SCHEMBL1710961 0.87 ALDH1A1 (1.00) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL15899792 0.87 ALDH1A1 (0.76) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL15575170 0.86 ALDH1A1 (0.73) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL17479214 0.85 ALDH1A1 (0.76) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL28309662 0.85 LMNA (0.72) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL17479352 0.85 ALDH1A1 (0.76) ALDH1A1LMNAKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107001283-B FLT3 receptor antagonists 国家健康与医学研究院 2021-05-25 CN disclosed
EP-3174859-B1 FLT3 RECEPTOR ANTAGONISTS INST NAT SANTE RECH MED (FR) 2020-04-29 EP disclosed
US-10065937-B2 FLT3 receptor antagonists INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) 2018-09-04 US disclosed
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2017-08-17 US disclosed
EP-3174859-A1 FLT3 RECEPTOR ANTAGONISTS INSERM - Institut National de la Santé et de la Recherche Médicale (FR) 2017-06-07 EP disclosed
WO-2016016370-A1 FLT3 RECEPTOR ANTAGONISTS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2016-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233354-A1 FLT3 RECEPTOR ANTAGONISTS FLT3, CSF1R, CSF3R ALDH1A1 2419/4885LMNA 4733/4885KMT2A 1531/4885
US-10065937-B2 FLT3 receptor antagonists FLT3, CSF1R, CSF3R ALDH1A1 2419/4885LMNA 4733/4885KMT2A 1531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.